434 related articles for article (PubMed ID: 11729491)
1. [Urinary tumor marker for urothelial cancer].
Ohtani M; Iwasaki A; Shiraiwa H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
[TBL] [Abstract][Full Text] [Related]
2. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer].
Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K
Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195
[TBL] [Abstract][Full Text] [Related]
4. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
Kurokawa S; Morita T; Muraishi O; Tokue A
Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
8. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
9. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
[TBL] [Abstract][Full Text] [Related]
10. Comparison of screening methods in the detection of bladder cancer.
Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
[TBL] [Abstract][Full Text] [Related]
13. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer.
Abbate I; D'Introno A; Cardo G; Marano A; Addabbo L; Musci MD; Pagliarulo A; Correale M; Quaranta M
Anticancer Res; 1998; 18(5B):3803-5. PubMed ID: 9854500
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers of urinary tract carcinoma].
Kikuchi H
Rinsho Byori; 2004 Apr; 52(4):371-80. PubMed ID: 15164607
[TBL] [Abstract][Full Text] [Related]
17. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
[TBL] [Abstract][Full Text] [Related]
18. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
19. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma].
Miyoshi Y; Matsuzaki J; Miura T
Hinyokika Kiyo; 2001 Jun; 47(6):379-83. PubMed ID: 11496392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
